Top 10 Biopharmaceutical Company Selects Model N’s GPM Solutions

Life Sciences industry continues to demand an end-to-end, enterprise class solution to manage timely global pricing REDWOOD SHORES, CA – December 19, 2013 – Model N, Inc. (NYSE: MODN), a leading [...]

Life Sciences industry continues to demand an end-to-end, enterprise class solution to manage timely global pricing

REDWOOD SHORES, CA – December 19, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced that a top ten biopharmaceutical company has selected Model N Global Price Management (GPM), the rebranded offering of Model N’s International Reference Pricing (IRP) solution, as a foundation to drive strategic global pricing. Model N believes that its GPM solution is the only enterprise-grade, Software-as-a-Service (SaaS) offering for global price management in the life sciences. Model N GPM is purpose-built to fully automate global reference pricing processes between life sciences pricing and market access teams worldwide. In an industry where timing is everything, the solution will eliminate time consuming inefficiencies that arise during the data-to-information-to-execution stages across global pricing.

Model N GPM helps pharmaceutical, biopharmaceutical, and medical device companies that sell into multiple countries maximize revenues by reducing price erosion and comply with global pricing regulations. With recent customer go-lives and a new product release, Model N GPM is well-positioned as the emerging standard solution for life sciences companies. Pricing and market access teams leverage Model N GPM to realize better prices, execute global pricing strategies more effectively, and drive global price governance.

The decision to select Model N GPM came after the company realized its need for an end-to-end global pricing and market access system that could integrate into its existing SAP ERP system. The company realized it could no longer evaluate local country pricing and launches without projecting the impacts on referencing countries, and their overall worldwide business. Model N’s GPM solution was chosen to allow the company to better manage pricing governance, facilitate a true picture of pricing with a global pricing database, and make timely global pricing decisions alongside shifts in the market. Implementation is slated to span across a couple of quarters from kick-off to go-live.

Current approaches to global price management often include spreadsheets, homegrown solutions, or ad-hoc consulting projects. There are many disadvantages to these alternatives such as inaccurate or lagging data, slow time to value, lack of flexibility to market fluctuations, and low or no visibility into the impact of global price changes. In a recent survey*, more than half (58 percent) of pharmaceutical company respondents believe the challenges of global drug pricing are not well understood across their business, significantly hampering efforts to reduce revenue leakages and margin erosion. Further, the need to link pricing strategy with price execution is seen as the biggest challenge in implementing a successful global pricing initiative (cited by 36 percent), followed by a lack of clear, unified processes and governance (cited by 28 percent).

“Ministries of Health in European countries, with also parts of Latin America and Asia, are accentuating their pressure on drug prices and are resorting to price referencing more frequently. In this more complex, more dynamic environment pharmaceutical manufacturers need to make quick strategic pricing decisions that minimize margin erosion – this requires an easy-to-use, integrated solution that ensures data quality, global collaboration, and systematic simulation analysis,” said Ali Tore, vice president of strategic markets at Model N. “Model N GPM gives our customers the confidence that they can accurately monitor future price changes and eliminate unwanted repercussions in other markets.”

“We are excited to welcome another pharmaceutical giant to the Model N family,” said Chris Larsen, senior vice president and chief sales officer at Model N. “Industry leaders such as these are embarking on a mission to drive cohesive global pricing strategies, and we look forward to supporting them as a strategic partner.”

About Model N Global Price Management

Model N Global Price Management helps global manufacturers mitigate reference pricing risk and profitability erosion through a powerful combination of data management, software applications, and best practices, including:

  • Global Pricing Database: Manage price lists, calendar of price events, fx rates, volume forecasts in a single global repository
  • Rule Definitions & Calculations: Consolidate reference pricing rules — country baskets, formulas, timing, channel, formal/informal, etc.
  • Global Price Governance: Administer user roles and rights; manage approval routes; trigger alerts, acknowledgement or escalation
  • Simulation Analytics & Reporting: Access price change impact reports and referencing country reports, create ad-hoc reports and charts
  • Launch Optimization: Identify best combinations of launch date and price in each country
  • Cloud Delivery: Optimize time to value and reduce capital outlays through rapid cloud deployment; built on the force.com platform

*Worldwide poll of 700 senior life sciences professionals taken by Model N at a recent eyeforpharma webinar

Resources:

About Model N

 

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

 

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

New Release of Model N Global Price Management Helps Drive Even Better Price Execution, Collaboration, and Governance

SaaS solution now includes new tracking and mapping features, deeper customization, and enhanced visibility to manage complex pricing mechanisms REDWOOD SHORES, CA – December 12, 2013 – Model N, [...]

SaaS solution now includes new tracking and mapping features, deeper customization, and enhanced visibility to manage complex pricing mechanisms

REDWOOD SHORES, CA – December 12, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced updates to its global price management offering for life sciences manufacturers. Model N Global Price Management, is an enterprise-grade SaaS solution that helps pharmaceutical and biopharmaceutical companies that sell into multiple countries maximize pharmaceutical prices, and reduce margin erosion. The latest version provides users with an updated launch tracker feature for capturing and tracking launch-related dates, price level mapping to keep track of price levels across all countries, and new settings for deeper levels of approvers and more customized data visibility.

“Model N Global Price Management is a true SaaS solution, giving us the flexibility to deliver new features as they are requested by our customers,” said Arnaud Grunwald, strategic market initiative executive for global pricing and market access at Model N. “The features that are now available to our customers provide an even deeper level of detail and customization to help pharmaceutical companies reduce the cost of delivering healthcare to patients by controlling product pricing at a global level.”

Key product enhancements include:

  • Launch Tracker: Gives global market access and pricing teams the ability to collaboratively capture launch-related dates (such as market authorization date, price submission date, price publication date, reimbursement submission date, reimbursement approval date), as well as launch prices. The information is consolidated into easy-to-use reports and made available for launch bench-marking.
  • Price Level Mapping: Allows users to map all price levels across all countries in order to create accurate cross-country reports and effectively compare similar price levels across countries, allowing users to better understand how different countries might refer to the same price level while producing a more holistic view of prices from country-to-country.
  • Increased Approval Levels and Data Visibility: Managers can now set up to 10 levels of approvers and up to five users in each level in the price change request process. The new release also gives users the ability to set a user’s data visibility based on product family, giving them access to data for the countries and product families they are assigned to. This significantly simplifies the look and feel of the application while protecting confidential data.

Resources:

Model N Global Price Management

Model N Blog: Global Market Access’ Path to being a True Competitive Advantage

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N to Present at the J.P. Morgan SMid Cap Conference

SaaS solution now includes new tracking and mapping features, deeper customization, and enhanced visibility to manage complex pricing mechanisms REDWOOD SHORES, CA – December 3, 2013 – Model N, [...]

SaaS solution now includes new tracking and mapping features, deeper customization, and enhanced visibility to manage complex pricing mechanisms

REDWOOD SHORES, CA – December 3, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced that Sujan Jain, Senior Vice President and Chief Financial Officer, will present at the J.P. Morgan SMid Cap Conference in Chicago, IL.

This presentation is scheduled for Tuesday, December 10, 2013 at 3:45 p.m. Eastern Time, or 12:45 p.m. Pacific Time. A live webcast of the presentation will be accessible from the investor relations page of the Model N website at http://investor.modeln.com/.

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Presents at Largest Gross-to-Net Conference for Life Sciences Leaders

Life Sciences finance executives gather in Philadelphia to tackle the challenges and complexities of gross-to-net PHILADELPHIA, PA – November 20, 2013 – Model N, Inc. (NYSE: MODN), a leading [...]

Life Sciences finance executives gather in Philadelphia to tackle the challenges and complexities of gross-to-net

PHILADELPHIA, PA – November 20, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, will present today at CBI’s 3rd Annual Gross-to-Net Accounting & Accruals conference, currently running in Philadelphia. This year’s conference is the go-to forum on the latest forecasting, accounting, and accrual methods being implemented throughout the life sciences industry.

Model N Vice President of Product Management, Ajay Dawar, will present (Wednesday, Nov. 20 at 2:20 p.m. EST) in the track on practical applications for gross-to-net forecasting, calculations, and reporting. Dawar’s presentation “Best Practices to Achieve Price Transparency: A Tale of Two Gross-to-Nets” will explore how two industry leaders, one a med-tech company and the other a global pharma company, effectively employed reliable, repeatable gross-to-net visibility into their organizations. Attendees of this session will learn new ways to overcome change management challenges, how to obtain and leverage executive buy-in, and mistakes to avoid when taking on increased gross-to-net visibility efforts.

“Having complete visibility into your business is the holy grail in life sciences business management,” said Ken Pulverman, vice president of marketing at Model N. “We are pleased to be delivering these solutions today, and are really looking forward to highlighting two customer success stories at one of the largest gross-to-net conferences of the year.”

Model N is a proud sponsor of CBI’s 3rd Annual Gross-to-Net Accounting & Accruals conference, and will be exhibiting in the Regency Foyer at the Loews Hotel in Philadelphia, November 19-20.

Resources:

Revenue Management for Pharmaceutical Companies

Revenue Management for Medical Device Companies

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Releases New Enhancements to Life Sciences Suite, Introduces Powerful Utilization Data Management Functionality

Responding to industry demand, Model N’s latest release brings ScriptValidate to customers, along with advancements to its embedded BI engine REDWOOD CITY, CA – November 14, 2013 – Model N, Inc. [...]

Responding to industry demand, Model N’s latest release brings ScriptValidate to customers, along with advancements to its embedded BI engine

REDWOOD CITY, CA – November 14, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced the general availability for Release 5.7 of its industry-leading Life Science Revenue Management suite. Life science manufacturers can now deploy the company’s latest prescription data scrubbing and verification application, ScriptValidate, which can be deployed independently or integrated with Model N’s Revenue Management Suite, either on premise or in the cloud. In addition, Model N’s life sciences customers will benefit from an upgrade to their reporting functionality through its latest Cognos update, as well as time zone and timer service enhancements for improved global data deployment and job management.

Release 5.7 Highlights

With Release 5.7, life sciences customers can now leverage Model N ScriptValidate, the only cloud-based rebate claims validation solution designed with the visibility and control necessary to quickly identify overpayments and save money. Features of ScriptValidate include:

  • Holistic approach to utilization of data management which prevents over payment of claims by ensuring rebates are only paid on valid prescription data.
  • Seamless integration to Model N Commercial and Regulatory Suites for contract-specific validations and downstream rebate processing; can be deployed independently or integrated with Model N’s Life Sciences Revenue Management Suite, either on premise or in the cloud.
  • Intuitive and efficient user interface that facilitates easier adoption and operation to manage exceptions and spot data trends and anomalies.

Release 5.7 also adds new platform enhancements across the suite to support the unique business needs of the life sciences industry. Additional key highlights of this release include:

  • Embedded business intelligence reporting upgrade for advanced reporting and decision support functionality provided by an integrated end-to-end revenue management system.
  • Advanced support of global data deployments via new time zone enhancements.

“The enhancements we’ve made to our life sciences suite, with the addition of ScriptValidate, addresses some of the most significant business challenges faced by life sciences manufacturers that rely on rebates and incentives to maximize wholesaler and distributor relationships,” said Rene Larro, vice president of product management at Model N. “Our latest developments within the Model N suite will continue to help our customers prevent revenue leakage, gain more value from their rebates and incentives business, and increase visibility for their business drivers with better decision support and upgraded global revenue management capabilities.”
Resources:
Model N ScriptValidate
Model N Life Sciences
Model N Revenue Management

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Announces Date of Fourth Quarter and Fiscal Year 2013 Financial Results

REDWOOD CITY, CA – October 23, 2013 – Model N, Inc. (NYSE: MODN),  a leading revenue management solutions provider to the life science and technology industries, plans to announce financial [...]

REDWOOD CITY, CA – October 23, 2013 – Model N, Inc. (NYSE: MODN),  a leading revenue management solutions provider to the life science and technology industries, plans to announce financial results for the fourth quarter and fiscal year 2013 after market close on Tuesday, November 19, 2013. The company also will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to review its financial results and business outlook.

The conference call can be accessed by dialing (877) 705-6003 from the United States or (201) 493-6725 internationally with conference ID 10000768, and a live webcast and replay of the conference call can be accessed from the investor relations page of Model N’s website at investor.modeln.com. Following the completion of the call through 11:59 p.m. ET on November 26, 2013, a telephone replay will be available by dialing (877) 870-5176 from the United States or (858) 384-5517 internationally with recording access code 10000768.

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Investor Relations Contact:

ICR for Model N

Greg Kleiner, 650-610-4998

investorrelations@modeln.com

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Names Christopher Larsen as SVP & Chief Sales Officer

Proven Sales Leader Brings Sales Execution, Executive Vision, and Track Record of Scaling Companies REDWOOD CITY, CA – October 21, 2013 – Model N, Inc. (NYSE: MODN), the leading revenue [...]

Proven Sales Leader Brings Sales Execution, Executive Vision, and Track Record of Scaling Companies

REDWOOD CITY, CA – October 21, 2013 – Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, today announced that it has appointed Christopher Larsen as Senior Vice President & Chief Sales Officer.

As a 25-year veteran in the industry, Larsen has a proven track record of success in the enterprise software market. Prior to joining Model N, Larsen held leadership positions at SAP, TIBCO and Infragistics. He brings extensive global operations experience and vertical industry go-to-market expertise as well as a unique focus on continual customer value creation.

“Chris brings to Model N proven leadership and the know-how to scale global sales organizations. These are skills that are paramount as we bring the benefits of Revenue Management to more companies,” said Model N Founder, Chairman and CEO Zack Rinat. “I am excited to have Chris join the Model N team.”

Larsen’s previous successes in creating efficient and scalable global field processes across the customer engagement lifecycle have resulted in strong customer loyalty, best-in-class operational execution and highly productive global field teams. Both at SAP and TIBCO, Larsen demonstrated a strong ability to operate at scale.

As President of SAP North America, Larsen drove a $1.2 billion operation and the go-to-market strategy, development and execution for the US subsidiary of the world’s largest enterprise application software company, leading over 2,000 employees across sales, pre-sales, consulting, industry marketing, alliances and channels. At TIBCO, Larsen drove the global field transformation for an organization of over 400 customer-facing sales and alliances professionals, transitioning it from a technology-driven engagement model to a strategic solution and customer-centric engagement model. His success has been driven by establishing scalable and repeatable pipeline management, forecasting, account and opportunity management, channel and alliance management, and professional services processes. Most recently, Larsen was the Chief Operating Officer and General Manager of the Mobile Business App Division at Infragistics, a leading provider of UX and UI development tools.

“I am delighted to join Model N at such a pivotal time in its growth,” said Larsen. “Model N is pioneering the new category of Revenue Management enterprise software. Being able to effectively manage revenue execution is an unmet need at virtually all the companies I have worked with over the years. When I saw the benefits and potential of this software category, I jumped at the opportunity to become part of this successful team and market opportunity.”

Resources

Follow Model N on Twitter

Follow Model N on LinkedIn

Follow Model N on Facebook

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N to Speak on Global Pricing for Medical Device Companies

Model N will cover developing a well-rounded pricing strategy and staying ahead of pricing market trends in two signature sessions. CHICAGO, IL – September 16, 2013 – Model N, Inc. (NYSE: [...]

Model N will cover developing a well-rounded pricing strategy and staying ahead of pricing market trends in two signature sessions.

CHICAGO, IL – September 16, 2013 – Model N, Inc. (NYSE: MODN),  a leading revenue management solutions provider to the life science and technology industries, today announced it will present at this week’sMedical Device Strategic Pricing Conference in Chicago, Sept. 16-17. As Medical Device companies prepare for a new healthcare environment, this year’s conference focuses on how industry leaders can build the analytics, leverage the best practices, and utilize the value-based pricing models needed to remain competitive.

Model N Senior Director of Industry Solutions, Gop Rao, will moderate the panel, “Incorporating Cross-Department Knowledge to Create a Well-Rounded Pricing Strategy” (Mon., Sept. 16 at 1:30 – 2:15 p.m. CDT) this afternoon. The panel will feature executives from Wright Medical Technology, Johnson & Johnson Global Surgery and Biomet Orthopedics. The discussion will examine the business case for why and how pricing executives should take a financial viability approach to their pricing strategies while pulling knowledge across departments to strengthen those strategies.

Model N will also lead the presentation, “Utilizing IRP to Stay Ahead of Market Trends” on day two of the conference (Tues., Sept. 17 at 9:15 – 10 a.m. CDT). In this session, Rao will co-present with Model N Senior Director of Global Pricing and Market Access Solutions, Arnaud Grunwald, on how medical device companies, looking to expand their product line globally, can leverage cross border reference pricing when determining the price of those products. Through their review of major European and Asian market trends and reimbursement models, the session will provide attendees with vital information to be considered when determining the pricing strategy for a medical technology distributed on a global level.

“In today’s changing, global healthcare environment, pricing medical technologies has become a uniquely complex undertaking,” said Ken Pulverman, vice president of marketing at Model N. “The Model N team is pleased to contribute to this collaborative platform for advancing the decision making, analytical skills, and overall strategies needed to improve pricing and business results for medical device companies.”

In addition to presenting, Model N will be exhibiting as a silver sponsor at this year’s conference. Model N will also hold a networking dinner tonight at 6:15 p.m. for conference attendees at Ristorante Quartino. Interested parties may RSVP at the Model N booth during the conference or email Wendy Mayerson,wmayerson@modeln.com.

Resources:

Model N Solution Brief: International Reference Pricing

Model N Big Ideas: Global Pricing

Model N for Medical Device Companies

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Presents at the Largest, Annual Summit for Medicaid Drug Rebate Program (MDRP) Executives

ndustry stakeholders convene in Chicago to discuss and plan for 2014 MDRP best practices, challenges, and opportunities. REDWOOD CITY, CA – September 10, 2013 – Model N, Inc. (NYSE: MODN), a [...]

ndustry stakeholders convene in Chicago to discuss and plan for 2014 MDRP best practices, challenges, and opportunities.

REDWOOD CITY, CA – September 10, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced it will present at this week’s 18th annual summit on the Medicaid Drug Rebate Program (MDRP) currently running in Chicago. The summit is the foremost event of the year for all things government pricing, rebates, and regulatory in pharma with over 500 MDRP executives expected in attendance.

Model N Senior Director of Product Management, Scott Medberry, participated in yesterday’s 340B symposium for pharmaceutical manufacturers as a panelist during the “340B Hot Topics” session. The discussion covered insights on how manufacturers are getting ahead of enforcement scrutiny and avoiding HRSA audits, what manufacturers should consider doing to maintain compliance with accurate reporting of 340B ceiling prices, and lessons manufacturers can learn from HRSA’s audits of 340B covered entities.

Model N will lead a presentation this afternoon (Tues., Sept. 10 at 2:15 p.m. CDT) during the Contract Management, Business Analytics and Systems Implementation Track. In this session, “Taking Control of Bundling,” Model N Director of Global Customer Service and Support, Jesse Mendelsohn, and Model N Solution Architect, Gloria Kee, will discuss the incentive programs that are requiring the spread of bundled discounts and how to avoid noncompliance with Centers for Medicare & Medicaid Services (CMS) mandates. The presentation will also focus on areas such as managing and classifying agreements, reallocation methodology, and performing reallocations.

“The annual summit on the MDRP is the best opportunity for industry experts, pharma leaders, and government regulators to gather, discuss, and plan for the issues that impact the pharma industry in the space of government pricing,” said Ken Pulverman, vice president of marketing at Model N. “This an important annual event for Model N, and its customers, and provides valuable insights and guidance for the entire industry for the year to come.”

Model N is a gold sponsor at this year’s summit and is exhibiting at booth #15. Model N will also hold a networking dinner tonight at 7 p.m. for summit delegates at the Frontera Grill. Interested parties may RSVP at the Model N booth during the summit or email Wendy Mayerson, wmayerson@modeln.com.

Resources:

Model N Pharma Regulatory Compliance

Model N Pharma Chargebacks, Incentives, Rebates

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Provides Business Update and Preliminary Fiscal 2014 Guidance

Industry stakeholders convene in Chicago to discuss and plan for 2014 MDRP best practices, challenges, and opportunities. REDWOOD CITY, CA – September 9, 2013 – Model N, Inc. (NYSE: MODN), a [...]

Industry stakeholders convene in Chicago to discuss and plan for 2014 MDRP best practices, challenges, and opportunities.

REDWOOD CITY, CA – September 9, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today provided a business update and preliminary guidance for the first quarter and full year fiscal 2014.

“Our current revenue visibility has caused us to reduce our financial expectations for fiscal 2014,” said Zack Rinat, Model N’s Founder, Chairman, and Chief Executive Officer. “We remain focused on recruiting a new sales leader to resolve the sales execution challenges we discussed on last quarter’s earnings conference call. We continue to believe that our market leading products, large market opportunity, proven value proposition, and strong pipeline of opportunities position the company well for the long-term.”

As of September 9, 2013, Model N is providing the following guidance:

  • For the first quarter of fiscal 2014 ending December 31, 2013, the Company expects:
    – Total revenue to be in the range of $20.0 million to $21.0 million
  • For the full fiscal year ending September 30, 2014, the Company expects:- Total revenue to be in the range of $70.0 million to $80.0 million
Business Update Conference Call:

Model N will host a conference call today at 2:00 PM Pacific Time (5:00 PM Eastern Time) to review this preliminary guidance for both the first fiscal quarter and the full fiscal year 2014. To access the call, please dial (877) 705-6003 in the U.S. or (201) 493-6725 internationally. Passcode is 10000248. A live webcast of the conference will be accessible from Model N’s website at: http://investor.modeln.com. Following the completion of the call through 11:59 p.m. ET on September 16, 2013, a recording will be available for replay at:http://investor.modeln.com and a telephone replay will be available by dialing (877) 870-5176 in the U.S. or (858) 384-5517 internationally with recording access code 10000248.

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N International Reference Pricing Solution Reduces Margin Erosion

Major Pharmaceutical Companies Can Reduce Margin Erosion by Almost 40 percent with Deeper Modification and Automation Capabilities REDWOOD CITY, CA – July 26, 2013 – Model N, Inc. (NYSE: MODN), a [...]

Major Pharmaceutical Companies Can Reduce Margin Erosion by Almost 40 percent with Deeper Modification and Automation Capabilities

REDWOOD CITY, CA – July 26, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced the latest version of its International Reference Pricing (IRP) offering. Model N IRP, is an enterprise-grade SaaS solution that helps pharmaceutical and biopharmaceutical companies that sell into multiple countries, maximize pharmaceutical prices, and reduce margin erosion. The latest version provides users with an enhanced user experience, improved data verification processes, and new simulation modeling capabilities.

“Referencing rules and relationships have become increasingly complex, and austerity measures are increasing governmental focus on improving drug costs. Pharmaceutical customers need a solution that can fully automate and distribute reference pricing management processes,” said Ali Tore, Co-founder and Vice President of Analytics at Model N. “Many of the largest global biopharma manufacturers are our customers. We have a deep understanding of global pharmaceutical pricing and contracting. The latest enhancements to our IRP solution provide an even deeper level of personalization and automation to help our customers tackle this very complex challenge.”

Key product enhancements include:

  • Enhanced User Experience

Model N IRP provides quick and visual access to personalized data for each global pricing manager, allowing them to easily view what might impact their country, as well as their reference network of countries. By presenting the data in an easy-to-understand format, users can easily obtain the insights they need to take vital actions.

  • Data Verification Processes

New processes guide users to verify the data relevant to them by providing them with the right information at the right time. This process engages all relevant users to prompt them to check their data, ultimately leading to increased user adoption and engagement, and better data quality.

  • Simulation Modeling

Simulations can produce predictive analytic insights that help global pricing managers anticipate future pricing changes. Advanced modeling functionality also helps demonstrate how a price change today might impact various countries in the future.

In a recent survey* of global pricing experts representing nearly one-third of the largest pharmaceutical companies, respondents indicated:

  • There is significant room for improvement when it comes to operationalizing global pricing processes;
  • Global pricing experts are often underequipped when it comes to collaborating and making fast data-driven decisions based on analytics; and
  • More than 50 percent plan to invest in new solutions to fix outdated systems that lack automation, ease-of-use and maintainability

Additionally, major global pharmaceutical companies have recently selected Model N to manage their international reference pricing processes. One large biopharma company implemented Model N IRP to manage product launches and pricing changes in more than 60 countries after realizing the pricing teams were using error-prone manual processes that didn’t provide insight into how pricing changes would impact other markets strategically.

Model N IRP has enabled them to reduce pricing erosion by 40 percent in the European Union (from 2.5 percent to 1.5 percent), a multi-million figure impact. The new solution has automated thousands of price changes, enhanced accuracy, and reduced non-compliance.

*Model N 2013 Global Pricing Survey

Resources:

• Model N Global Pricing and International Reference Pricing (IRP)

• Model N IRP Infographic

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Announces Date of Third Quarter Fiscal 2013 Financial Results

REDWOOD CITY, CA – July 16, 2013 – Model N, Inc. (NYSE: MODN),  a leading revenue management solutions provider to the life science and technology industries, plans to announce financial results [...]

REDWOOD CITY, CA – July 16, 2013 – Model N, Inc. (NYSE: MODN),  a leading revenue management solutions provider to the life science and technology industries, plans to announce financial results for the third quarter fiscal 2013 after market close on Thursday, August 8, 2013. The company also will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to review its financial results and business outlook.

The conference call can be accessed by dialing (877) 705-6003 from the United States or (201) 493-6725 internationally with conference ID 417636, and a live webcast of the conference call can be accessed from the investor relations page of Model N’s website at investor.modeln.com. Following the completion of the call through 11:59 p.m. ET on August 15, 2013, a recorded replay will be available on the company’s website, and a telephone replay will be available by dialing (877) 870-5176 from the United States or (858) 384-5517 internationally with recording access code 417636.

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Pharmaceutical Companies Detect and Prevent Revenue Leakage with SaaS Rx Rebate Validation

Model N’s Fully Automated ScriptValidate Solution Potentially Saves Companies Millions in Rebate Overpayments REDWOOD CITY, CA – June 25, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue [...]

Model N’s Fully Automated ScriptValidate Solution Potentially Saves Companies Millions in Rebate Overpayments

REDWOOD CITY, CA – June 25, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced its latest product offering,ScriptValidate. ScriptValidate is an automated, SaaS application that helps pharma manufacturers detect and prevent massive revenue leakage by using industry-standard and advanced detection methods to efficiently and accurately scrub prescription-level rebate claims.

In recent years, drug rebate volume and rates have increased significantly as both commercial and government payers seek new ways to change the healthcare cost equation. In this environment, pharma companies are straining to validate claims due to the sheer volume of data and diversity of formats. Model N ScriptValidate not only scrubs out incorrect lines in this data but also verifies rebate eligibility against contractually negotiated business rules and thresholds, potentially saving companies millions in averted rebate overpayments. The scrubbed data can then be sent downstream to Model N or other Managed Care rebates solutions for payment processing.

Unlike outsourced validation services and other offerings, ScriptValidate gives pharma Managed Care teams drill-down access to rich data sets that can provide deep insights into Managed Care business trends and performance without the hassle of managing an on-premise deployment. With maintenance, support, and upgrades handled in the Cloud, customers can reduce internal IT resource strain and be assured the solution is keeping pace with industry changes.

“It is not unusual for drug manufacturers to pay out several billion dollars annually in rebate liabilities and until now, there has never been a complete Cloud-based solution that can fully automate rebate validation to reduce this major source of revenue leakage,” explains Vijay Rao, Product Manager, Model N. “Model N ScriptValidate is the only pharma validation solution that combines the resource benefits of outsourcing this function with the data visibility and control of enterprise-class software.”

Supporting Links

ScriptValidate Infographic 

ScriptValidate Solution Brief 

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

White House Honors Model N CEO Zack Rinat as Champion of Change

Immigrant Spirit and Diversity Critical to Model N’s Success REDWOOD CITY, CA – May 30, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and [...]

Immigrant Spirit and Diversity Critical to Model N’s Success

REDWOOD CITY, CA – May 30, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, today announced that its founder and CEO Zack Rinat has been selected by the White House as a Champion of Change. As part of the Champions of Change program, the White House regularly recognizes different groups of Americans who are making positive changes in their community. Mr. Rinat was selected as one of the immigrant innovators and entrepreneurs who are helping create American jobs, grow the economy, and make the United States more competitive.

Mr. Rinat was honored at an event at the White House on May 29, where he participated on a panel, sharing his past work experiences as well as challenges and opportunities he has encountered since coming to the United States from Israel. “As I look back at my career as a successful entrepreneur, my background as an immigrant has enhanced every important decision I have made. I came to the United States eager to disrupt the status quo and take advantage of the vast educational opportunities, the open business climate, and the exceptional diverse workforce in order to build a successful company,” said Zack Rinat, founder and CEO of Model N.

Mr. Rinat’s background as an immigrant helped him identify issues that global companies face, resulting in new business opportunities and technology innovations. For example, Model N pioneered a new technology category of Revenue Management, which allows customers to improve revenue performance across the globe.

“We realized that our customers needed a way to better manage how revenue is collected and accounted for, ultimately allowing them to recoup billions of dollars annually,” Mr. Rinat said. “In building this company, I have built relationships with others who shared my vision, many of whom also come from immigrant backgrounds. This spirit contributes greatly to the culture of our company. To me this award is really for the customers, partners, and employees of Model N. They are the true champions of change.”

Mr. Rinat served as a company commander and Captain in the Special Forces of the Israeli Defense Forces. After graduating from the Technion (Israel Institute of Technology), Mr. Rinat built complex systems in Israel. Mr. Rinat immigrated to the United States when he was 30 years old. Upon being accepted at Harvard Business School, Mr. Rinat moved to Boston with his family, bringing only a few suitcases between them. Mr. Rinat made this decision as he felt the United States offered the best foundation for entrepreneurship.

Prior to Model N, Mr. Rinat co-founded and ultimately served as President and Chief Executive Officer of NetDynamics, Inc., an application server software company, before its acquisition by Sun Microsystems in 1998, where he served as the Vice President and General Manager of the NetDynamics business unit. From 1998-1999, Mr. Rinat served as a founding member of the Board of Directors of TradingDynamics, a provider of a B2B Auction Platform until its acquisition by Ariba. From 2005 to 2012, he also served on the Board of Directors of Conduit Ltd., a provider of cloud-based solutions for web publishers, and as the Chairman of the Board of Directors from 2005 to 2011. Previously, Mr. Rinat held senior management positions in operations, marketing, and engineering at Silicon Graphics, Inc., and at Advanced Technology Israel. He holds an MBA from Harvard Business School and a BA in computer science from the Technion (Israel Institute of Technology).

Resources: 

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Announces Date of Second Quarter Fiscal 2013 Financial Results

Model N’s Fully Automated ScriptValidate Solution Potentially Saves Companies Millions in Rebate Overpayments REDWOOD CITY, CA – April 11, 2013 – Model N, Inc. (NYSE: MODN), a provider of revenue [...]

Model N’s Fully Automated ScriptValidate Solution Potentially Saves Companies Millions in Rebate Overpayments

REDWOOD CITY, CA – April 11, 2013 – Model N, Inc. (NYSE: MODN), a provider of revenue management solutions for the life science and technology industries, plans to announce financial results for the second quarter fiscal 2013 after market close on Tuesday, May 7, 2013. The company also will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to review its financial results and business outlook.

The conference call can be accessed by dialing (888) 503-8169 from the United States or (719) 325-2454 internationally with conference ID 4807849, and a live webcast of the conference call can be accessed from the investor relations page of Model N’s website at investor.modeln.com. Following the completion of the call through 11:59 p.m. ET on May 14, 2013, a recorded replay will be available on the company’s website, and a telephone replay will be available by dialing (877) 870-5176 from the United States or (858) 384-5517 internationally with recording access code 4807849.

Investor Relations Contact:

ICR for Model N

Greg Kleiner, 650-610-4998


investorrelations@modeln.com



or



Media Contact:

Model N

Kristin Lee, 650-610-4717
Marketing

klee@modeln.com

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Announces Exercise of Over-Allotment Option

REDWOOD CITY, CA – March 21, 2013 – Model N, Inc. (NYSE: MODN), a provider of revenue management solutions for the life science and technology industries, today announced that the underwriters of [...]

REDWOOD CITY, CA – March 21, 2013 – Model N, Inc. (NYSE: MODN), a provider of revenue management solutions for the life science and technology industries, today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,011,000 shares of common stock from the company. As a result, the total initial public offering size is 7,751,000 shares of common stock, which consists of 7,011,000 shares of common stock to be sold by Model N and 740,000 shares of common stock to be sold by the selling stockholder. All shares sold in the offering are being sold at a price to the public of $15.50. Model N will not receive any proceeds from the sale of shares by the selling stockholders.

J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint bookrunning managers for the offering, and Stifel, Nicolaus & Company, Incorporated, Pacific Crest Securities LLC, Piper Jaffray & Co., and Raymond James & Associates, Inc. are acting as co-managers for the offering.

The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204; or Deutsche Bank Securities Inc., 60 Wall Street, New York, New York 10005, Attention: Prospectus Department, by calling (800) 503-4611, or by e-mailing prospectus.cpdg@db.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investor Relations Contact:

ICR for Model N

Greg Kleiner, 650-610-4998


investorrelations@modeln.com



or



Media Contact:

Model N

Kristin Lee, 650-610-4717
Marketing

klee@modeln.com

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Lists IPO on the New York Stock Exchange – Celebrates First Day as a Publicly-Traded Company

NEW YORK, CA – March 20, 2013 – Redwood Shores, Calif.-based Model N, Inc., a leading revenue management solutions provider to the life science and technology industries, opened for trading today [...]

NEW YORK, CA – March 20, 2013 – Redwood Shores, Calif.-based Model N, Inc., a leading revenue management solutions provider to the life science and technology industries, opened for trading today on the New York Stock Exchange (NYSE) under the ticker symbol “MODN” after its initial public offering. GETCO Securities LLC is the Designated Market Maker for the company’s stock.

Founder, Chairman and CEO Zack Rinat, accompanied by members of Model N’s leadership team, commemorated the company’s first day of trading by ringing the NYSE Opening BellSM and visiting the trading floor to witness the stock opening.

“Becoming a publicly traded company on the NYSE is recognition that Revenue Management software is a proven source of competitive advantage for companies in the life sciences and the technology industries. Furthermore it is a testament to our customers, partners, and employees daring to pioneer a new software category,” said Zack Rinat, Founder, Chairman, and CEO of Model N.

“We are delighted to welcome Model N to the NYSE’s growing community of technology companies,” said Scott R. Cutler, Executive Vice President, Head of Global Listings, NYSE Euronext. “Model N is a leader in revenue management solutions offering life science and technology companies around the globe a suite of innovative tools and services to support their distinctive business needs.  We congratulate Model N on its first day as a publicly-traded company and look forward to sharing a long and fruitful partnership with Model N and its shareholders.”

For more information on NYSE Euronext’s listings business and to learn about trends in the IPO market, please visit the NYSE Euronext IPO Center.

 

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Model N Announces Pricing of Initial Public Offering

Shares to Trade on NYSE under Ticker Symbol “MODN” REDWOOD CITY, CA – March 19, 2013 – Model N, Inc., a provider of revenue management solutions for the life science and technology [...]

Shares to Trade on NYSE under Ticker Symbol “MODN”

REDWOOD CITY, CA – March 19, 2013 – Model N, Inc., a provider of revenue management solutions for the life science and technology industries, today announced the pricing of its initial public offering of 6,740,000 shares of its common stock, including 6,000,000 shares from the company and 740,000 shares from a selling stockholder, at a price to the public of $15.50 per share. The shares are expected to begin trading on the New York Stock Exchange on March 20, 2013, under the symbol “MODN.” In addition, the company has granted the underwriters a 30-day option to purchase up to 1,011,000 additional shares of common stock.

J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint bookrunning managers for the offering, and Stifel, Nicolaus & Company, Incorporated, Pacific Crest Securities LLC, Piper Jaffray & Co., and Raymond James & Associates, Inc. are acting as co-managers for the offering.

The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204; or Deutsche Bank Securities Inc., 60 Wall Street, New York, New York 10005, Attention: Prospectus Department, by calling (800) 503-4611, or by e-mailing prospectus.cpdg@db.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investor Relations Contact:

ICR for Model N

Greg Kleiner, 650-610-4998

investorrelations@modeln.com

or

Media Contact:

Model N

Kristin Lee, 650-610-4717

Marketing

klee@modeln.com

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Revenue Management Leaders from Life Sciences and Technology Companies Recognized for Innovation, Globalization, and Excellence in Analytics

Top Companies Recognized at Model N RAINMAKER for Improving Sales and Overall Organizational Efficiency, Driving Better Financial Results with Revenue Management REDWOOD CITY, CA – March 7, 2013 [...]

Top Companies Recognized at Model N RAINMAKER for Improving Sales and Overall Organizational Efficiency, Driving Better Financial Results with Revenue Management

REDWOOD CITY, CA – March 7, 2013 – Model N, Inc., Model N announced yesterday the recipients of the RAINMAKER Awards at its ninth annual Global Revenue Management summit in Phoenix, AZ. Each year, Model N recognizes the companies that have driven tremendous results by transforming their business processes, for innovation and globalization of Revenue Management. The recipients for the 2013 RAINMAKER Awards are:

Corning Life Sciences

Revenue Management Visionary

Abbot Diabetes Care

Revenue Management Best Practices

Nokia

Revenue Management Globalization

Salix Pharmaceuticals

Revenue Management Innovation

Allergan

Revenue Management Analytics

Micron

Revenue Management Passion for the Journey

The RAINMAKER Awards were presented yesterday during the conference’s Welcome Address to an audience of over 400 Life Sciences and Technology executives and professionals.

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Global Revenue Management Providing Life Sciences and Technology Companies with the Architectural Blueprint Needed for Maximizing Revenue

Record Number of Life Sciences and Technology Companies Gather at Model N RAINMAKER 2013, Bringing Sales Effectiveness, Global Responsiveness, Channel Performance, and Regulatory Compliance to [...]

Record Number of Life Sciences and Technology Companies Gather at Model N RAINMAKER 2013, Bringing Sales Effectiveness, Global Responsiveness, Channel Performance, and Regulatory Compliance to the Forefront of Discussion for Revenue Management Leaders

REDWOOD SHORES, CA – March 6, 2013 – RAINMAKER 2013 – Model N, Inc., Model N’s ninth-annual Global Revenue Management summit, opened today at the Arizona Biltmore in Phoenix to a sellout crowd of Life Science and Technology leaders and innovators. The theme of this year’s event — Architecting Revenue — points to how Model N’s Revenue Management systems are providing companies with the blueprint needed for maximizing revenue. This year’s attendees and speaker lineup features experts from across both industries, representing close to100 top Life Sciences and Technology organizations and companies.

Architecting a Global Revenue Management Foundation

In the welcome address this morning, President and CEO, Zack Rinat showcased Model N’s milestones from the past year including a record number of customer go-lives and a positive outlook for the growth of Revenue Management in the coming year. Co-founder & Vice President of Analytics, Ali Tore, followed with a breakdown of industry trends that are driving continual investment in Global Revenue Management solutions within Life Sciences and Technology companies. Highlights included:

  • The launch of Model N International Reference Pricing Solution for Life Sciences Manufacturers for building a truly Global Revenue Management foundation
  • Record number of go lives over the last 12 months with 39 for 25 customers across the Life Sciences and the High Tech sectors
  • Significant expansion of Revenue Management Intelligence with investments in two of Model N’s key analytics products, Price ImpACT and Channel ImpACT
  • Release of Field ImpACT Mobile, Model N’s first product designed and optimized for the iPad to be used in multiple mobile scenarios by Pharmaceutical sales reps
Business Tracks for Driving Success

RAINMAKER 2013 will deliver industry insights and best practices to attendees through a new agenda format of business tracks, aligned with the business processes and value themes that are top of mind for Life Sciences and Technology leaders.

Featured Sessions
  • Health Care in the 21st Century: The Case For Global Revenue Management with Abbott Diabetes Care, Abbott Diagnostics Division, and HighPoint Solutions
  • Teardown Live! with IHS, a live breakdown of a consumer electronic to understand the underlying price and channel implications
  • Pricing Panel: Central vs. Regional Pricing Organization with Auxilium Partners, Maxim Integrated, Linear Technology, ON Semiconductor, NXP, and CSR
  • From Dx to Rx: Why Reform Makes Collaboration Critical for Manufacturer Success with Truven Health Analytics
  • Industry Leader Panel: Pricing to Profitability with Corning Life Sciences, and Deloitte Consulting
  • Industry Leader Panel: Maximizing Managed Markets with IMS Health, Johnson & Johnson, and Actelion
  • Determining Opportunity Value Using TAM not Volume with Atmel
  • Optimizing Design Win Tracking and Aligning the Sales Force with Cirrus Logic
  • Regulatory State of the State 2013 for Biopharma and Med Tech with King & Spalding
  • Industry Leader Panel: Regulatory Compliance with King & Spalding, IMS Health, and Johnson & Johnson
  • The Gross-To-Net Advantage: Minimizing Financial Risk with Medicis
  • New Trends for Ship & Debit in Asia with McKinsey & Company
  • Industry Leader Panel: Extracting the Data You Need from the Channel with Atmel, McKinsey & Company, PMC-Sierra, and Linear Technology
Special Guest and Keynote Sessions
  • RAINMAKER Keynote, Geoff Colvin, Senior Editor at Large, FORTUNE, who will speak on trends in the global economy affecting Revenue Management
  • “Whose Revenue Is It Anyway?” with Greg Proops and Jeff Davis of “Whose Line is it Anyway?” fame
Record Investment from Industry Sponsors

RAINMAKER 2013 has received an unprecedented level of sponsorships, showcasing the prominent role Model N’s ecosystem partners are playing in delivering value to Model N customers. The Partner Pavilion features the largest number of exhibiting implementation and technology experts in the Life Sciences and High Tech industries at RAINMAKER.

  • Global Strategic Implementation Sponsor: HighPoint Solutions
  • Strategic Implementation Sponsor, Gaining Insights Track: Alliance Life Sciences
  • Strategic Implementation Sponsor, Managed Markets Track: IMS Health
  • Strategic Implementation Sponsor, Optimizing Model N Track: Mindlance Life Sciences
  • Sponsor, Pricing to Profitability Track: Deloitte Consulting
  • Strategic Advisory Sponsor, Med Tech Compliance: Huron Consulting Group
  • Ecosystem Sponsor: Oracle

Model N’s semi-annual customer and executive advisory board meetings will also be held concurrently at RAINMAKER 2013.

“Economic uncertainty is reshaping how companies think about competitiveness, core enterprise processes, and growth,” noted Ken Pulverman, VP of Corporate Marketing, Model N. “Our RAINMAKER attendees look to this conference and Model N for the most current thinking on how to most effectively manage their revenue generation and revenue risk management processes.“

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Atmel, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

page 1 of 2